A Novel Inhibitor Prevents the Peripheral Neuroparalysis of Botulinum Neurotoxins

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Azarnia Tehran, Domenico ^a   Zanetti, Giulia ^a   Leka, Oneda ^a   Lista, Florigio ^b   Fillo, Silvia ^b   Binz, Thomas ^c   Shone, Clifford C ^d   Rossetto, Ornella ^a   Montecucco, Cesare ^a   Paradisi, Cristina ^a   Mattarei, Andrea ^a   Pirazzini, Marco ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Army Medical and Veterinary Research Center   (Italy)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; NEUROTOXIN; SEMICARBAZONE DERIVATIVE; SNARE PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DIAPHRAGM; DISEASE MODEL; DRUG EFFECTS; MALE; METABOLISM; MOUSE; NERVE CELL; PARALYSIS; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; SYNTHESIS; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BOTULINUM TOXINS; DIAPHRAGM; DISEASE MODELS, ANIMAL; MALE; MICE; NEURONS; NEUROTOXINS; PARALYSIS; PERIPHERAL NERVOUS SYSTEM DISEASES; SEMICARBAZONES; SNARE PROTEINS;

EID: 84949973970     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17513     Document Type: Article

References (61)

1. Johnson, E. A., Montecucco, C. Botulism. Handb Clin Neurol 91, 333-368 (2008).
2. Rossetto, O., Pirazzini, M., Montecucco, C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12, 535-549 (2014).
3. Arnon, S. S. et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 285, 1059-1070 (2001).
4. Centers for Disease Control and Prevention. D. o. H. a. H. S. Possession, use, and transfer of select agents and toxins; biennial review. Final rule. Fed Regist 77, 61083-61115 (2012).
5. Davletov, B., Bajohrs, M., Binz, T. Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins. Trends Neurosci. 28, 446-452 (2005).
6. Dressler, D. Clinical applications of botulinum toxin. Curr Opin Microbiol. 15, 325-336 (2012).
7. Rummel, A. Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Curr Top Microbiol Immunol 364, 61-90 (2013).
8. Binz, T., Rummel, A. Cell entry strategy of clostridial neurotoxins. J Neurochem. 109, 1584-1595 (2009).
9. Nishiki, T. et al. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem. 269, 10498-10503 (1994).
10. Dong, M. et al. SV2 is the protein receptor for botulinum neurotoxin A. Science. 312, 592-596 (2006).
11. Matteoli, M. et al. Synaptic vesicle endocytosis mediates the entry of tetanus neurotoxin into hippocampal neurons. Proc Natl Acad Sci USA 93, 13310-13315 (1996).
12. Colasante, C. et al. Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction. Mol Neurobiol 48, 120-127 (2013).
13. Harper, C. B. et al. Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism. J Biol Chem. 286, 35966-35976 (2011).
14. Montal, M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 79, 591-617 (2010).
15. Pirazzini, M. et al. On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments. Biochimica et Biophysica Acta (BBA)-Biomembranes. http://dx.doi.org/10.1016/j.bbamem.2015.08.014.
16. Montecucco, C., Schiavo, G., Dasgupta, B. R. Effect of pH on the interaction of botulinum neurotoxins A, B and E with liposomes. Biochem J. 259, 47-53 (1989).
17. Fischer, A., Montal, M. Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem. 282, 29604-29611 (2007).
18. Pirazzini, M. et al. The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals. FEBS Lett 587, 150-155 (2013).
19. Pirazzini, M. et al. Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. Cell Rep 8, 1870-1878 (2014).
20. Zanetti, G. et al. Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism. Biochem Pharmacol, doi: 10.1016/j.bcp.2015.09.023 (2015).
21. Binz, T. Clostridial neurotoxin light chains: devices for SNARE cleavage mediated blockade of neurotransmission. Curr Top Microbiol Immunol 364, 139-157 (2013).
22. Pantano, S., Montecucco, C. The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell Mol Life Sci, 71, 793-811 (2013).
23. Kozaki, S., Miyazaki, S., Sakaguchi, G. Development of antitoxin with each of two complementary fragments of Clostridium botulinum type B derivative toxin. Infect Immun 18, 761-766 (1977).
24. Barash, J. R., Arnon, S. S. A Novel Strain of Clostridium botulinum That Produces Type B and Type H Botulinum Toxins. J Infect Dis, 209, 183-191 (2013).
25. Smith, T. J. et al. Sequence Variation within Botulinum Neurotoxin Serotypes Impacts Antibody Binding and Neutralization. Infection and Immunity 73, 5450-5457.(2005).
26. Webb, R. P., Smith, T. J., Wright, P., Brown, J., Smith, L. A. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine 27, 4490-4497 (2009).
27. Gillespie, E. J. et al. Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses. Proc Natl Acad Sci USA 110, E4904-4912 (2013).
28. Eleopra, R. et al. Botulinum neurotoxin serotype D is poorly effective in humans: An in vivo electrophysiological study. Clinical Neurophysiology 124, 999-1004 (2013).
29. Jung, M. E., Chamberlain, B. T., Ho, C.-L. C., Gillespie, E. J., Bradley, K. A. Structure-Activity Relationship of Semicarbazone EGA Furnishes Photoaffinity Inhibitors of Anthrax Toxin Cellular Entry. ACS Medicinal Chemistry Letters 5, 363-367 (2014).
30. Lalli, G. et al. Functional characterisation of tetanus and botulinum neurotoxins binding domains. Journal of Cell Science 112, 2715-2724 (1999).
31. Restani, L. et al. Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS pathogens 8, e1003087 (2012).
32. Blum, F. C., Chen, C., Kroken, A. R., Barbieri, J. T. Tetanus Toxin and Botulinum Toxin A Utilize Unique Mechanisms To Enter Neurons of the Central Nervous System. Infection and Immunity 80, 1662-1669 (2012).
33. Kraszewski, K. et al. Synaptic vesicle dynamics in living cultured hippocampal neurons visualized with CY3-conjugated antibodies directed against the lumenal domain of synaptotagmin. The Journal of Neuroscience 15, 4328-4342 (1995).
34. Keller, J. E., Cai, F., Neale, E. A. Uptake of botulinum neurotoxin into cultured neurons. Biochemistry. 43, 526-532 (2004).
35. Simpson, L. L. Ammonium chloride and methylamine hydrochloride antagonize clostridial neurotoxins. J Pharmacol Exp Ther. 225, 546-552 (1983).
36. Pirazzini, M., Rossetto, O., Bolognese, P., Shone, C. C., Montecucco, C. Double anchorage to the membrane and intact interchain disulfide bond are required for the low pH induced entry of tetanus and botulinum neurotoxins into neurons. Cell Microbiol. 13, 1731-1743 (2011).
37. Strotmeier, J. et al. Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a gangliosidedependent manner. Biochem J. 431, 207-216 (2010).
38. Rasetti-Escargueil, C., Liu, Y., Rigsby, P., Jones, R. G., Sesardic, D. Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies. Toxicon 57, 1008-1016 (2011).
39. Smith, T. J., Hill, K. K., Raphael, B. H. Historical and current perspectives on Clostridium botulinum diversity. Research in Microbiology 166, 290-302 (2015).
40. Montecucco, C., Rasotto, M. B. On botulinum neurotoxin variability. MBio 6 (2015).
41. Fischer, A. et al. Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci USA 106, 1330-1335 (2009).
42. Montal, M. Redox regulation of botulinum neurotoxin toxicity: therapeutic implications. Trends Mol Med 20, 602-603 (2014).
43. Jähne, S., Rizzoli, S. O., Helm, M. S. The structure and function of presynaptic endosomes. Experimental Cell Research 335, 172-179 (2015).
44. Cousin, M. A. Synaptic Vesicle Endocytosis and Endosomal Recycling in Central Nerve Terminals: Discrete Trafficking Routes Neuroscientist 21, 413-423 (2015).
45. Saheki, Y., De Camilli, P. Synaptic vesicle endocytosis. Cold Spring Harb Perspect Biol 4 (2012).
46. Wucherpfennig, T., Wilsch-Braüninger, M., González-Gaitán, M. Role of Drosophila Rab5 during endosomal trafficking at the synapse and evoked neurotransmitter release. The Journal of Cell Biology 161, 609-624 (2003).
47. Morgan, J. R., Comstra, H. S., Cohen, M., Faundez, V. Presynaptic membrane retrieval and endosome biology: defining molecularly heterogeneous synaptic vesicles. Cold Spring Harb Perspect Biol 5, a016915 (2013).
48. De Hoop, M. J. et al. The involvement of the small GTP-binding protein Rab5a in neuronal endocytosis. Neuron 13, 11-22 (1994)
49. Pellett, S., Tepp, W. H., Scherf, J. M., Johnson, E. A. Botulinum Neurotoxins Can Enter Cultured Neurons Independent of Synaptic Vesicle Recycling. PLoS One 10, e0133737 (2015).
50. Keller, J. E., Neale, E. A., Oyler, G., Adler, M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 456, 137-142 (1999).
51. Eleopra, R., Tugnoli, V., Rossetto, O., De Grandis, D., Montecucco, C. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256, 135-138 (1998).
52. Meunier, F. r. A., Lisk, G., Sesardic, D., Dolly, J. O. Dynamics of motor nerve terminal remodeling unveiled using SNAREcleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Molecular and Cellular Neuroscience 22, 454-466 (2003).
53. Keller, J. E. Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 139, 629-637 (2006).
54. Diril, M. K., Wienisch, M., Jung, N., Klingauf, J., Haucke, V. Stonin 2 Is an AP-2-Dependent Endocytic Sorting Adaptor for Synaptotagmin Internalization and Recycling. Developmental Cell 10, 233-244 (2006).
55. Sun, S., Tepp, W. H., Johnson, E. A., Chapman, E. R. Botulinum neurotoxins B and E translocate at different rates and exhibit divergent responses to GT1b and low pH. Biochemistry. 51, 5655-5662 (2012).
56. Willig, K. I., Rizzoli, S. O., Westphal, V., Jahn, R., Hell, S. W. STED microscopy reveals that synaptotagmin remains clustered after synaptic vesicle exocytosis. Nature 440, 935-939 (2006).
57. Peng, L., Tepp, W. H., Johnson, E. A., Dong, M. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog. 7, e1002008 (2011).
58. Simpson, L. The life history of a botulinum toxin molecule. Toxicon 68, 40-59 (2013).
59. Fagan, R. P., McLaughlin, J. B., Middaugh, J. P. Persistence of botulinum toxin in patients' serum: Alaska, 1959-2007. The Journal of infectious diseases 199, 1029-1031.(2009).
60. Sheth, A. N. et al. International outbreak of severe botulism with prolonged toxemia caused by commercial carrot juice. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 47, 1245-1251 (2008).
61. Koepke, R., Sobel, J., Arnon, S. S. Global occurrence of infant botulism, 1976-2006. Pediatrics 122, e73-82 (2008).